HC Wainwright Issues Optimistic Outlook for Ocugen Earnings

Ocugen, Inc. (NASDAQ:OCGN) – HC Wainwright lifted their Q1 2026 EPS estimates for shares of Ocugen in a report issued on Wednesday, March 25th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.05) per share for the quarter, up from their prior estimate of ($0.06). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen’s Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at $0.18 EPS, FY2029 earnings at $0.84 EPS and FY2030 earnings at $1.79 EPS.

Other equities analysts have also issued research reports about the stock. Chardan Capital restated a “buy” rating and set a $7.00 target price on shares of Ocugen in a research report on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Oppenheimer began coverage on shares of Ocugen in a report on Wednesday, March 11th. They set an “outperform” rating and a $10.00 price objective for the company. Wall Street Zen upgraded Ocugen from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Canaccord Genuity Group assumed coverage on Ocugen in a report on Tuesday, March 17th. They issued a “buy” rating and a $12.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.75.

Ocugen Stock Down 4.6%

OCGN stock opened at $1.87 on Friday. The company has a market capitalization of $613.17 million, a price-to-earnings ratio of -8.13 and a beta of 2.75. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.06 and a current ratio of 1.06. Ocugen has a fifty-two week low of $0.57 and a fifty-two week high of $2.73. The business’s 50 day moving average price is $1.74 and its two-hundred day moving average price is $1.54.

Ocugen (NASDAQ:OCGN) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The company had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.86 million.

Institutional Investors Weigh In On Ocugen

Several large investors have recently added to or reduced their stakes in OCGN. Caitong International Asset Management Co. Ltd grew its holdings in Ocugen by 76,831.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 82,317 shares of the company’s stock worth $111,000 after acquiring an additional 82,210 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Ocugen in the 4th quarter valued at about $106,000. NewEdge Advisors LLC lifted its position in shares of Ocugen by 69.0% in the 4th quarter. NewEdge Advisors LLC now owns 135,460 shares of the company’s stock worth $183,000 after purchasing an additional 55,305 shares during the period. Millennium Management LLC lifted its position in shares of Ocugen by 29.7% in the 4th quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock worth $7,285,000 after purchasing an additional 1,234,268 shares during the period. Finally, Balyasny Asset Management L.P. bought a new position in shares of Ocugen during the fourth quarter valued at approximately $196,000. 10.27% of the stock is owned by hedge funds and other institutional investors.

More Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised several 2026 quarterly EPS forecasts (Q1–Q4 moved toward ($0.05) from ($0.06)), boosted FY2026 and materially raised long‑range revenue/earnings assumptions (FY2028–FY2030), and reiterated a “Buy” rating with a $10 price target — a constructive analyst endorsement that supports longer‑term upside. HC Wainwright Issues Positive Forecast for Ocugen (NASDAQ:OCGN) Stock Price
• Positive Sentiment: Chardan Capital assigned a Buy rating on Ocugen, adding another buy‑side vote that may attract momentum buyers or traders looking for analyst‑driven catalysts. Ocugen (NASDAQ:OCGN) Earns Buy Rating from Chardan Capital
• Neutral Sentiment: Consensus for FY2026 EPS remains negative (around ($0.20) per share), so while some analysts are lifting estimates, the market still expects a loss this year — keeping Ocugen in speculative/biotech territory.
• Negative Sentiment: Noble Financial lowered near‑term EPS estimates (Q3 2026 to ($0.07) and Q4 2026 to ($0.08); FY2026 to ($0.26)), signaling concern about near‑term performance and adding selling pressure from cautious shops.
• Negative Sentiment: Clinical setback: Phase II data for OCU410 in an eye disease trial showed lower lesion reduction versus earlier results (despite a reported 31% improvement), which triggered the immediate stock weakness as investors reassess clinical and regulatory risk. Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.